Kristin Patrick
Known title: DirectorCIK: 0001769529
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
SLE Included in Communication Services Movers List. Super League Enterprise was highlighted in a Benzinga report listing communication services stocks with notable intraday movement on Monday. The stock is currently trading near its 52-week low, a context that may explain its inclusion in a list of volatile movers. Technical indicators show the price is near support levels, reflecting the recent volatility captured in the news.
Transaction History
| NAGE | ▲ Buy | Option Exercise | 3,000 | $5K | 8/23/2024 | View on chart |
| NAGE | ▲ Buy | Option Exercise | 20,000 | $33K | 8/23/2024 | View on chart |
| NAGE | ▼ Sell | Open Market | 23,000 | $82K | 8/23/2024 | View on chart |
| SLE | ▲ Buy | Grant | 27,027 | — | 9/7/2023 | View on chart |
| SLE | ▲ Buy | Grant | 60,000 | — | 6/16/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
NAGE linked to new preclinical study on CD38 and NAD+ decline
A new preclinical study identified CD38 as a driver of age‑related NAD+ decline and showed that nicotinamide riboside can improve pregnancy outcomes in animal models. The research also reported lower NAD+ levels in placental tissue from older mothers. Niagen Bioscience clarified that it did not conduct, fund, or design the study and that the NR used was not its proprietary Niagen ingredient. The findings relate to the company’s focus on NAD+‑boosting products and may draw attention to its pipeline.
NAGE linked to new preclinical study on CD38 and NAD+ decline. A new preclinical study identified CD38 as a driver of age‑related NAD+ decline and showed that nicotinamide riboside can improve pregnancy outcomes in animal models. The research also reported lower NAD+ levels in placental tissue from older mothers. Niagen Bioscience clarified that it did not conduct, fund, or design the study and that the NR used was not its proprietary Niagen ingredient. The findings relate to the company’s focus on NAD+‑boosting products and may draw attention to its pipeline.